Moderna Inc. (MRNA), is a leading biotechnology company in the nascent field of mRNA (messenger RNA) therapeutics. MRNA is best known for its leading Covid-19 vaccine candidate, mRNA-1273, which will likely be the company’s first commercialized product.
As of late 2020, no mRNA-based medicines have been approved by the FDA or any other regulatory agency.
In late November of 2020, MRNA announced that mRNA-1273 had an astonishingly high efficacy of 94.1%, which is comparable to Pfizer and BioNTech’s vaccine candidate, BNT162b2. We expect mRNA-1273 to be FDA-approved for emergency use by early 2021.
Download the case study to learn more about CFRA's analysis on Moderna.
Please visit our website for more examples of CFRA’s fundamental research.